drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (autologous anti-CD19 CAR T cells)
drug_description
Autologous, genetically modified anti-CD19 chimeric antigen receptor (CAR) T-cell therapy made from a patient’s T cells; engineered to express an anti-CD19 CAR that, upon binding CD19 on B cells, induces antigen-dependent T-cell activation, proliferation, and cytotoxic killing, with expected on-target B-cell aplasia and risk of cytokine release.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous patient T cells engineered to express an anti‑CD19 chimeric antigen receptor. Binding CD19 on malignant and normal B cells triggers CAR signaling, activating and expanding the T cells and inducing cytokine release and perforin/granzyme‑mediated cytotoxic killing, resulting in depletion of CD19+ cells (on‑target B‑cell aplasia).
drug_name
RC19D2 (dinorencel)
nct_id_drug_ref
NCT06047197